Sector: Health Care
Director information for JOHNSON & JOHNSON (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Daniel E. Pinto | Vice Chairman | 63 | ["Demonstrated excellence in executive and operational leadership within a large global corporation","Extensive experience overseeing international markets with notable experience in emerging markets in Eastern Europe, the Middle East, Africa and Asia","Expertise in accounting, capital markets and investment banking"] | ["Audit","Compensation & Benefits","Special Committee – Orthopaedics Separation"] | 2026 |
| D. E. Pinto | Vice Chairman, JPMorganChase | 63 | [] | ["Audit Committee","Special Committee - Orthopaedics Separation"] | 2026 |
| E. A. Woods | Chief Executive Officer, Advocate Health | 61 | [] | ["C","Regulatory Compliance & Sustainability Committee"] | 2026 |
| Eugene A. Woods | Chief Executive Officer; Compensation & Benefits Committee Chair | 61 | ["More than three decades of experience overseeing healthcare facilities including hospitals, academic institutions and other community-based systems","Proven record of business expansion through geographic growth, digital innovation, and mergers and acquisitions","Deep understanding of patient needs in rural and urban populations"] | ["Chair, Compensation & Benefits","Member, Regulatory Compliance & Sustainability"] | 2026 |
| H. Joly | Former Executive Chairman, Chairman, President and Chief Executive Officer, Best Buy Co., Inc. | 66 | [] | ["C","Audit Committee","Nominating & Corporate Governance Committee","Special Committee - Orthopaedics Separation"] | 2026 |
| Hubert Joly | Independent Director; Audit Committee Chair | 66 | ["Extensive strategic, operational and financial expertise relevant to international corporations","Led the successful digital transformation of businesses focusing on the customer experience","Experience in business transformation and human capital management"] | ["Chair, Audit","Member, Nominating & Corporate Governance","Member, Special Committee – Orthopaedics Separation"] | 2026 |
| J. A. Doudna | Principal Investigator, Doudna Lab; Founder, Innovative Genomics Institute, Professor of Biochemistry, Biophysics and Structural Biology, Founder, Laboratory for Genomics Research, University of California, Berkeley | 62 | [] | ["Nominating & Corporate Governance Committee","Science & Technology Committee"] | 2026 |
| J. Duato | Chairman of the Board and Chief Executive Officer, Johnson & Johnson | 63 | [] | [] | 2026 |
| Jennifer A. Doudna, Ph.D. | Independent Director | 62 | ["Principal Investigator, Doudna Lab","Founder, Innovative Genomics Institute","Professor, Biochemistry, Biophysics and Structural Biology","Founder, Laboratory for Genomics Research","Nobel Prize Recipient in Chemistry (2020)","Pioneer in the field of biochemistry, having co-discovered the simplified genome editing technique CRISPR-Cas9","Expertise in scientific research and innovation","Leader in integration of scientific research and ethics"] | ["Nominating & Corporate Governance","Science & Technology"] | 2026 |
| J. G. Morikis | Former Executive Chairman, President and Chief Executive Officer, The Sherwin-Williams Company | 62 | [] | ["Audit Committee"] | 2026 |
| Joaquin Duato | Management Director; Chairman of the Board and CEO | 63 | ["Decades of broad experience spanning multiple business segments, geographies and functions","Globally minded, purpose-driven business leader with a deep commitment to Our Credo values"] | ["Chair, Finance","Finance"] | 2026 |
| John G. Morikis | Independent Director | 62 | ["Expertise in executive and operational leadership relevant to global industry","Insight and extensive experience in global expansion, business management, strategic planning and transformation, finance, supply chain optimization and product innovation","Led successful technology advancements to enhance the customer experience and drive operational efficiency","Deep understanding of complex healthcare systems, including its delivery systems, funding sources, regulations and current trends"] | ["Audit","Compensation & Benefits"] | 2026 |
| M. A. Hewson | Former Executive Chairman, Chairman, President and Chief Executive Officer, Lockheed Martin Corporation | 72 | [] | ["C","Nominating & Corporate Governance Committee","Special Committee - Orthopaedics Separation"] | 2026 |
| Marillyn A. Hewson | Lead Director; Lead Independent Director | 72 | ["Expertise in executive and operational leadership in a global, regulated industry","Insight and experience in global business management, strategic planning, cybersecurity, finance, supply chain, leveraged services and manufacturing","Expertise in government relations and human capital management"] | ["Chair, Nominating & Corporate Governance","Member, Compensation & Benefits","Member, Finance","Chair, Special Committee – Orthopaedics Separation","Nominating & Corporate Governance"] | 2026 |
| Mark A. Weinberger | Independent Director; Regulatory Compliance & Sustainability Committee Chair | 64 | ["Experience leading a global business and working at the highest levels of government","Track record of driving transformative change in the public and private sectors during periods of unprecedented disruption","Expertise in accounting, compliance and corporate governance, with a strong commitment to corporate purpose"] | ["Chair, Regulatory Compliance & Sustainability","Member, Audit","Member, Special Committee – Orthopaedics Separation"] | 2026 |
| Mark B. McClellan, M.D., Ph.D. | Independent Director | 62 | ["Extensive experience in public health policy and regulation, including as Commissioner of the U.S. Food and Drug Administration and Administrator for the U.S. Centers for Medicare & Medicaid Services","Broad knowledge of, and unique insights into, the challenges facing the healthcare industry"] | ["Regulatory Compliance & Sustainability","Science & Technology"] | 2026 |
| Mary C. Beckerle | Science & Technology Committee Chair | [] | [] | 2026 | |
| Mary C. Beckerle, Ph.D. | Independent Director | 71 | ["Distinguished Professor of Biology and Oncological Sciences at University of Utah","Chief Executive Officer Emerita at Huntsman Cancer Institute","Expertise in scientific research and organizational management in the healthcare arena","Active participant in national and international scientific affairs","Strong focus on patient experience"] | ["Chair, Science & Technology","Member, Regulatory Compliance & Sustainability"] | 2026 |
| M. A. Weinberger | Chair | ["audit committee financial expert","former Chairman and Chief Executive Officer, Ernst & Young LLP"] | ["Audit Committee","Regulatory Compliance & Sustainability Committee","Special Committee - Orthopaedics Separation"] | 2026 | |
| M. A. Weinberger(1) | Former Global Chairman and Chief Executive Officer, Ernst & Young | 64 | [] | ["C"] | 2026 |
| M. B. McClellan | Director, Duke-Robert J. Margolis, MD, Center for Health Policy, Duke University | 62 | [] | ["Regulatory Compliance & Sustainability Committee","Science & Technology Committee"] | 2026 |
| M. C. Beckerle | Distinguished Professor of Biology and Oncological Sciences, University of Utah; Chief Executive Officer Emerita, Huntsman Cancer Institute; Chair | 71 | [] | ["C","Regulatory Compliance & Sustainability Committee","Science & Technology Committee"] | 2026 |
| Nadja Y. West, M.D. | Independent Director | 64 | ["Proven executive and operational leadership","strategic planning and healthcare management","Expertise in government relations and human capital management","Operational crisis management and disaster response experience pertaining to global health issues","Extensive information security and cybersecurity experience"] | ["Regulatory Compliance & Sustainability","Science & Technology","Special Committee – Orthopaedics Separation"] | 2026 |
| N. Y. West | Former Lieutenant General, U.S. Army | 64 | [] | ["Regulatory Compliance & Sustainability Committee","Science & Technology Committee","Special Committee - Orthopaedics Separation"] | 2026 |
| P. A. Johnson | President, Wellesley College | 66 | [] | ["Nominating & Corporate Governance Committee","Science & Technology Committee"] | 2026 |
| Paula A. Johnson, M.D. | Independent Director | 66 | ["Expertise in medical research, public health and health policy","Visionary in understanding and improving the standard of care across distinct patient categories (notably in women’s health)","Proven leadership across complex organizations focused on cross-functional collaboration and increased inclusivity","Passionate educator focused on accessibility of STEM curriculum for diverse student populations"] | ["Nominating & Corporate Governance","Science & Technology"] | 2026 |
